Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: The CRESCEND study

被引:6
|
作者
Kim, Jae-Min [1 ]
Stewart, Robert [2 ]
Bae, Kyung-Yeol [1 ]
Yang, Su-Jin [1 ]
Yoon, Jin-Sang [1 ]
Jung, Sung-Won [3 ]
Lee, Min-Soo [4 ]
Yim, Hyeon-Woo [5 ]
Jun, Tae-Youn [6 ]
机构
[1] Chonnam Natl Univ, Sch Med, Dept Psychiat, Kwangju 501757, South Korea
[2] Inst Psychiat, Epidemiol Sect, London, England
[3] Keimyung Univ, Sch Med, Dept Psychiat, Taegu, South Korea
[4] Korea Univ, Coll Med, Dept Psychiat, Seoul 136705, South Korea
[5] Catholic Univ Korea, Coll Med, Dept Prevent Med, Seoul, South Korea
[6] Catholic Univ Korea, Coll Med, Dept Psychiat, Seoul, South Korea
关键词
Somatic disorder; Depressive disorder; Treatment outcome; Remission; Response; Korea; TREATMENT RESPONSE; CARE; POPULATION; DISABILITY; RECOVERY; HEALTH; TRIALS; AXIS;
D O I
10.1016/j.jpsychores.2011.05.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Physical and depressive disorders frequently co-occur, but effects of physical health on depression treatment outcomes have received little research. This study aimed to compare treatment outcomes between people with depressive disorder with and without comorbid physical disorders. Methods: A Korean nationwide sample of 723 people with depressive disorder initiated on antidepressant treatment, and re-evaluated at I, 2, 4, 8, and 12 weeks later. Assessment scales for evaluating depressive symptoms (HAMD), anxiety (HAMA), global severity (CGI-s), and functioning (SOFAS) were administered at baseline and every follow-up visit. Achievement of remission or response was defined only when these were maintained to the 12 week study endpoint or to the last follow-up examination, if earlier, with the date of the first observed remission point applied as the timing of remission. Logistic regression and Cox proportional hazards models were used. Results: Of the sample, 247 (34%) had at least one physical disorder. This was associated with lower socioeconomic status and more severe depressive symptoms at baseline, but was not associated with any treatment related characteristics including antidepressant type and regimen, concomitant medications, side effects, and duration of treatment period. After adjustment, patients with physical comorbidity responded more slowly and less often - particularly in domains of anxiety, global severity, and functioning (all p-values <.005). Conclusion: More intensive assessment and integrated treatment approaches are needed to facilitate treatment responses for depressive disorders in people with physical comorbidity. Future comparative studies between conventional and integrated treatment approaches are indicated for depressive disorders with physical comorbidity. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 50 条
  • [1] Gender differences in 12 week treatment outcomes in Korean depressive patients: a report of CRESCEND study
    Yang, S.
    Yoo, J.
    Bae, K.
    Kim, J.
    Shin, I.
    Kim, S.
    Yoon, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S337 - S338
  • [2] Comorbid physical disorders and 12 week treatment outcomes in Korean patients with depressive disorders
    Yoo, J. A.
    Kim, J. A.
    Yang, S. J.
    Kim, S. W.
    Shin, I. S.
    Yoon, J. S.
    Kim, J. B.
    Lee, M. S.
    Lim, H. W.
    Jun, T. Y.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S337 - S337
  • [3] Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study
    Kim, Jae-Min
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Seon-Young
    Yoon, Jin-Sang
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (01) : 41 - 50
  • [4] Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: The CRESCEND study
    Yang, Su-Jin
    Kim, Sun-Young
    Stewart, Robert
    Kim, Jae-Min
    Shin, Il-Seon
    Jung, Sung-Won
    Lee, Min-Soo
    Jeong, Seung-Hee
    Jun, Tae-Youn
    [J]. PSYCHIATRY RESEARCH, 2011, 189 (01) : 82 - 90
  • [5] Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders
    Jin, Yun-Tae
    Kim, Ha-Yeon
    Jhon, Min
    Kim, Ju-Wan
    Kang, Hee-Ju
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    [J]. PSYCHIATRY INVESTIGATION, 2022, 19 (10) : 866 - +
  • [6] Stressful events, stress perception and treatment outcomes in patients with depressive disorders: The CRESCEND study
    Kim, Jae-Min
    Kim, Sung-Wan
    Stewart, Robert
    Kang, Hee-Ju
    Shin, Il-Seon
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2011, 133 (03) : 528 - 536
  • [7] Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: The CRESCEND study
    Kim, Jae-Min
    Kim, Seon-Young
    Stewart, Robert
    Yoo, Joon-An
    Bae, Kyung-Yeol
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2011, 129 (1-3) : 183 - 190
  • [8] Factors associated with subjective quality of life in Korean patients with depressive disorders: the CRESCEND study
    Jung, Young-Eun
    Seo, Ho-Jun
    Song, Hoo Rim
    Woo, Young Sup
    Yim, Hyeon-Woo
    Sung, Hyung-Mo
    Lee, Min-Soo
    Kim, Jae-Min
    Jun, Tae-Youn
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 (06) : 967 - 974
  • [9] Factors associated with subjective quality of life in Korean patients with depressive disorders: the CRESCEND study
    Young-Eun Jung
    Ho-Jun Seo
    Hoo Rim Song
    Young Sup Woo
    Hyeon-Woo Yim
    Hyung-Mo Sung
    Min-Soo Lee
    Jae-Min Kim
    Tae-Youn Jun
    [J]. Quality of Life Research, 2012, 21 : 967 - 974
  • [10] Agomelatine for the Treatment of Patients with Fibromyalgia and Depressive Symptomatology: An Uncontrolled, 12-Week, Pilot Study
    Calandre, E. P.
    Slim, M.
    Garcia-Leiva, J. M.
    Rodriguez-Lopez, C. M.
    Torres, P.
    Rico-Villademoros, F.
    [J]. PHARMACOPSYCHIATRY, 2014, 47 (02) : 67 - 72